CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2023. The put-call ratio across all filers is 1.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $195 | +93.1% | 4,770 | +100.0% | 0.00% | +100.0% |
| Q1 2024 | $101 | -76.2% | 2,385 | -76.2% | 0.00% | -66.7% |
| Q4 2023 | $425 | +111.4% | 10,027 | +8.8% | 0.00% | +50.0% |
| Q3 2023 | $201 | -31.4% | 9,218 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $293 | +48.7% | 9,218 | +13.9% | 0.00% | 0.0% |
| Q1 2023 | $197 | -34.6% | 8,096 | -15.3% | 0.00% | -33.3% |
| Q4 2022 | $301 | -99.9% | 9,558 | +9.6% | 0.00% | +50.0% |
| Q3 2022 | $247,000 | +8.8% | 8,724 | +1.6% | 0.00% | 0.0% |
| Q2 2022 | $227,000 | -2.2% | 8,586 | +29.4% | 0.00% | 0.0% |
| Q1 2022 | $232,000 | -49.8% | 6,633 | -53.5% | 0.00% | 0.0% |
| Q4 2021 | $462,000 | +120.0% | 14,260 | +100.3% | 0.00% | 0.0% |
| Q3 2021 | $210,000 | – | 7,119 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 65,679,781 | $2,685,646,245 | 57.02% |
| Twin Securities, Inc. | 416,657 | $17,037,105 | 13.40% |
| Sand Grove Capital Management LLP | 919,023 | $37,578,850 | 10.99% |
| Perceptive Advisors | 10,794,876 | $441,402,480 | 10.63% |
| P SCHOENFELD ASSET MANAGEMENT LP | 796,440 | $32,566,432 | 7.87% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,353,694 | $96,242,547 | 4.60% |
| Avoro Capital Advisors LLC | 7,539,547 | $308,292,077 | 4.11% |
| Melqart Asset Management (UK) Ltd | 1,099,229 | $44,947,474 | 3.72% |
| Paradigm Biocapital Advisors LP | 2,330,508 | $95,294,472 | 3.65% |
| WATER ISLAND CAPITAL LLC | 766,933 | $31,360 | 3.33% |